Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
James Conklin is EVP, Americas at Adient. OQRO lists 11 transactions filed with the SEC under this name, the latest on Nov 17, 2026, each linked to the official Form 4.
EVP, Americas
Disclosures on record
11
Companies involved
1
As of the latest filing on , James Conklin reported holding 200,904 shares of Adient (ADNT), worth about $3.1M at the last close of $15 (Nov 18, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Adient ADNT | 200,904 | 201K direct | $15 | $3.1M | Nov 16, 2026 |
Is this James Conklin’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
AdientADNT
11 disclosures · Dec 2024 – Nov 2026 · 1 sold
Nov 12, 202695Kdisclosed Nov 17
DetailsOfficial recordNov 16, 20262,890disclosed Nov 17
DetailsOfficial recordNov 13, 20265,501disclosed Nov 17
DetailsOfficial recordNov 14, 20265,010disclosed Nov 17
DetailsOfficial recordMay 7, 202623Kdisclosed May 8
DetailsOfficial recordNov 17, 20251,694disclosed Nov 18
DetailsOfficial recordNov 13, 20255,262disclosed Nov 17
DetailsOfficial recordNov 13, 202547Kdisclosed Nov 17
DetailsOfficial recordNov 14, 20253,316disclosed Nov 17
DetailsOfficial recordNov 16, 20252,805disclosed Nov 17
DetailsOfficial recordDec 4, 2024Sold~$233Kdisclosed Dec 5
DetailsOfficial recordJames Conklin has no open-market purchase on record since 2023. Sales in 2 of the 4 years since 2023.
James Conklin reported 0 open-market purchases and 3 sales since 2023; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $355K2×2 trades |
| 2023 | — | $41K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 16, 2026, James Conklin reported holding 200,904 shares of Adient (ADNT). At the last close of $15 on Nov 18, 2026, that is about $3.1M. This is the stake disclosed in filings, not a net worth.
No public filing gives James Conklin's net worth. What SEC Form 4 shows is the stock stake: 200,904 shares of Adient (ADNT), about $3.1M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
James Conklin has no open-market purchase on record since 2023. Sales in 2 of the 4 years since 2023.
In SEC filings since 2023: no open-market purchase is on record; the latest open-market sale is from 2024.
Adient (ADNT), from 2023 to 2024: 0 purchases and 3 sales.
James Conklin reported 0 open-market purchases and 3 sales here, 2023 to 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.